NIKKEI 225
37,884.61 -575.47 (-1.50%) HANG SENG
17,144.12 -57.15 (-0.33%) CRUDE OIL
82.76 -0.05 (-0.06%) GOLD FUTURES
2,330.60 -7.80 (-0.33%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,709.77 -1,877.81 (-3.50%)
Compugen Ltd. (CGEN)
| Previous close | 1.9800 |
| Open | 1.9600 |
| Bid | 1.9000 x 400 |
| Ask | 1.9300 x 300 |
| Day's range | 1.9000 - 1.9850 |
| 52-week range | 0.5300 - 3.0300 |
| Volume | |
| Avg. volume | 587,938 |
| Market cap | 171.003M |
| Beta (5Y monthly) | 2.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.33 |
PR NewswireCompugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects' link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for
PR NewswireCompugen to Participate in Two Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming investor conferences in April:
Simply Wall St.Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 31% Discount?
Key Insights Compugen's estimated fair value is US$3.60 based on 2 Stage Free Cash Flow to Equity Current share price...
